In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli

Antimicrobial Agents and Chemotherapy
Suzannah M Schmidt-MalanRobin Patel

Abstract

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam-β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n = 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/>128 μg/ml for imipenem alone to 0.25/1 μg/ml. For isolates harboring blaCTX-M (n = 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 μg/ml (83% susceptible). For isolates harboring blaCMY-2 (n = 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 μg/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

References

Mar 4, 2000·Journal of Clinical Microbiology·C BornetC Bollet
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Laurent PoirelPatrice Nordmann
Jul 17, 2007·Clinical Microbiology Reviews·Anne Marie Queenan, Karen Bush
Mar 16, 2013·International Journal of Medical Microbiology : IJMM·Marco Maria D'AndreaGian Maria Rossolini
Apr 6, 2013·Journal of Medical Microbiology·Jeanette W P TeoRaymond T P Lin
May 15, 2013·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M N D BalmJ W P Teo
May 23, 2013·The Journal of Antimicrobial Chemotherapy·David M LivermoreShazad Mushtaq
Jan 1, 2012·Western Pacific Surveillance and Response Journal : WPSAR·Jeanette TeoRaymond Lin
Sep 11, 2013·Pathology·Tse Hsien KohEng Eong Ooi
Oct 31, 2014·New Microbes and New Infections·J W P TeoK T Hsien
Dec 23, 2014·Expert Opinion on Pharmacotherapy·Christian Eckmann, Joseph Solomkin
Jan 7, 2015·Saudi Journal of Biological Sciences·Sibhghatulla ShaikhMohammad Amjad Kamal
Mar 7, 2015·Mayo Clinic Proceedings·Shawn VasooPritish K Tosh
May 28, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaJohn Quale
Jul 15, 2015·The Annals of Pharmacotherapy·Allana J SucherMatthew Fete
Feb 19, 2016·Journal of Clinical Microbiology·Scott A CunninghamRobin Patel
Mar 24, 2016·International Journal of Antimicrobial Agents·Ling-Shan SyuePo-Ren Hsueh
Jun 4, 2016·International Journal of Antimicrobial Agents·Monica PavezElsa Masae Mamizuka
Jun 10, 2016·Therapeutics and Clinical Risk Management·Stephanie E GiancolaElizabeth B Hirsch
Jun 23, 2016·Cold Spring Harbor Perspectives in Medicine·Karen Bush, Patricia A Bradford

❮ Previous
Next ❯

Citations

Jun 21, 2019·The Journal of Antimicrobial Chemotherapy·Alan R NoelAlasdair P MacGowan
Jan 15, 2020·Current Infectious Disease Reports·Mandee NovalEmily Heil
Aug 21, 2020·Expert Review of Anti-infective Therapy·Nicolette TheriaultChristian E Sandrock
Apr 23, 2019·Expert Review of Anti-infective Therapy·Georgios L VoulgarisMatthew E Falagas
Nov 21, 2019·MSystems·Jessica Y El KhouryMarc Ouellette
Dec 4, 2020·Infection and Drug Resistance·Toni A Campanella, Jason C Gallagher
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Mar 9, 2021·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Tsung-Ying YangPo-Liang Lu
Mar 24, 2021·Antimicrobial Agents and Chemotherapy·Viivi H A HirvonenMarc W van der Kamp

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antibody Repertoire Diversity

Antibody repertoire diversity and its role during natural infection is a prerequisite for molecular and structural elucidation of functionally protective immunity. Discover the latest insights into antibody diversity here.